

Supplement Table 48. Composition of anti-inflammatory lipid-containing enteral nutrition formulations evaluated in randomized controlled trials (KQ19)

Study (year)	Population	Numbers of patient			% of total calories, lipids		% EPA+DHA+GLA on total lipid dosage	
		Total	Antioxidant-containing formulations	Control	Antioxidant-containing formulations	Control	Antioxidant-containing formulations	Control
Shirai, 2015 [135]	Sepsis-induced ARDS	40	20	20	EPA+DHA+GLA $\approx$ 5.8 (continuous EN)	35.2	5.3 (EPA $\approx$ 2.2 %, DHA $\approx$ 0.9 %, GLA $\approx$ 2.2 %)	
Stapleton, 2011 [139]	ALI patients	90	41	49	EPA+DHA $\approx$ 9.75 (fish oil capsules)	55.2	5.3 (EPA $\approx$ 2.2 %, DHA $\approx$ 0.9 %, GLA $\approx$ 2.2 %)	-
Rice, 2011 [301]	ALI patients	272	143	129	EPA+DHA+GLA $\approx$ 6.2 (bolus EN)	55.2	5.3 (EPA $\approx$ 2.2 %, DHA $\approx$ 0.9 %, GLA $\approx$ 2.2 %)	-
Grau-Carmona, 2011 [302]	Septic patients with ALI or ARDS	92	44	48	EPA+DHA+GLA $\approx$ 5.8 (continuous EN)	46.4	24 (EPA $\approx$ 12 %, DHA $\approx$ 5 %, GLA $\approx$ 7 %)	-
Elamin, 2012 [303]	Medical-surgical patients with ARDS	17	9	8	EPA+DHA+GLA $\approx$ 5.4 (continuous EN)	30.1	5.3 (EPA $\approx$ 2.2 %, DHA $\approx$ 0.9 %, GLA $\approx$ 2.2 %)	-
Parish, 2014 [304]	ARDS patients	60	30	30	EPA+DHA $\approx$ 3 (omega-3 supplement)	55.2	10 (EPA $\approx$ 3.6 %, DHA $\approx$ 2.4 %, GLA $\approx$ 4 %)	-

ARDS, acute respiratory distress syndrome; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; GLA, gamma-linolenic acid; ALI, acute lung injury.

